Statistical considerations in long-term efficacy evaluation of anti-cancer therapies
Anti-cancer therapy has been a significant focus of research. Developing and marketing various types and mechanisms of anti-cancer therapies benefit a variety of patients significantly. The long-term benefit to patients in evaluating the risk-benefit ratio of anti-cancer therapy has become a signifi...
Main Authors: | Ruobing Li, Jingyi Zhang, Jingzhao Wang, Jun Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1265953/full |
Similar Items
-
The role of the estimand framework in the analysis of patient-reported outcomes in single-arm trials: a case study in oncology
by: Doranne Thomassen, et al.
Published: (2024-11-01) -
Handling missing values in patient-reported outcome data in the presence of intercurrent events
by: Doranne Thomassen, et al.
Published: (2025-03-01) -
How to implement the ‘one patient, one vote’ principle under the framework of estimand
by: Naitee Ting
Published: (2023-07-01) -
Starting a conversation about estimands with public partners involved in clinical trials: a co-developed tool
by: Suzie Cro, et al.
Published: (2023-07-01) -
Violations of proportional hazard assumption in Cox regression model of transcriptomic data in TCGA pan-cancer cohorts
by: Zihang Zeng, et al.
Published: (2022-01-01)